Aberrant patterns of H3K4 and H3K27 histone lysine methylation occur across subgroups in medulloblastoma

详细信息    查看全文

• 作者：Adrian M. Dubuc (1) (2) (3)
  Marc Remke (1) (2) (3)
  Andrey Korshunov (4) (5) (6)
  Paul A. Northcott (6)
  Shing H. Zhan (7)
  Maria Mendez-Lago (7)
  Marcel Kool (6)
  David T. W. Jones (6)
  Alexander Unterberger (1) (2)
  A. Sorana Morrissy (1) (2)
  David Shih (1) (2) (3)
  John Peacock (1) (2) (3)
  Vijay Ramaswamy (1) (2) (3)
  Adi Rolider (1) (2)
  Xin Wang (1) (2) (3)
  Hendrik Witt (6)
  Thomas Hielscher (6)
  Cynthia Hawkins (1) (2) (3)
  Rajeev Vibhakar (8)
  Sidney Croul (9)
  James T. Rutka (1) (3)
  William A. Weiss (10)
  Steven J. M. Jones (7)
  Charles G. Eberhart (11)
  Marco A. Marra (7)
  Stefan M. Pfister (6)
  Michael D. Taylor (1) (2) (3)
  
• 关键词：MLL2 ; KDM6A ; Histone lysine methylation ; Medulloblastoma ; PRC2
• 刊名：Acta Neuropathologica
• 出版年：2013
• 出版时间：March 2013
• 年：2013
• 卷：125
• 期：3
• 页码：373-384
• 全文大小：1301KB
• 参考文献：1. Alimova I, Venkataraman S, Harris P, Marquez VE, Northcott PA (2012) Targeting the enhancer of zeste homologue 2 in medulloblastoma. Int J Cancer doi:10.1002/ijc.27455
  2. Andreu-Vieyra CV, Chen R, Agno JE, Glaser S, Anastassiadis K et al (2010) MLL2 is required in oocytes for bulk histone 3 lysine 4 trimethylation and transcriptional silencing. PLoS Biol 8(8):e1000453 journal.pbio.1000453">CrossRef
  3. Bots M, Johnstone RW (2009) Rational combinations using HDAC inhibitors. Clin Cancer Res 15(12):3970-977 CrossRef
  4. Ecke I, Petry F, Rosenberger A, Tauber S, Monkemeyer S et al (2009) Antitumor effects of a combined 5-aza-2′deoxycytidine and valproic acid treatment on rhabdomyosarcoma and medulloblastoma in Ptch mutant mice. Cancer Res 69(3):887-95 CrossRef
  5. Ellison DW, Onilude OE, Lindsey JC, Lusher ME, Weston CL et al (2005) beta-Catenin status predicts a favorable outcome in childhood medulloblastoma: the United Kingdom Children’s Cancer Study Group Brain Tumour Committee. J Clin Oncol 23(31):7951-957 CrossRef
  6. Fejes AP, Khodabakhshi AH, Birol I, Jones SJ (2011) Human variation database: an open-source database template for genomic discovery. Bioinformatics 27(8):1155-156 CrossRef
  7. Glaser S, Schaft J, Lubitz S, Vintersten K, van der Hoeven F et al (2006) Multiple epigenetic maintenance factors implicated by the loss of Mll2 in mouse development. Development 133(8):1423-432 CrossRef
  8. van Haaften G, Dalgliesh GH, Davies H, Chen L, Bignell G et al (2009) Somatic mutations of the histone H3K27 demethylase gene UTX in human cancer. Nat Genet 41(5):521-23 CrossRef
  9. Jones DT, Jager N, Kool M, Zichner T, Hutter B et al (2012) Dissecting the genomic complexity underlying medulloblastoma. Nature 488(7409):100-05 CrossRef
  10. Kool M, Koster J, Bunt J, Hasselt NE, Lakeman A et al (2008) Integrated genomics identifies five medulloblastoma subtypes with distinct genetic profiles, pathway signatures and clinicopathological features. PloS One 3(8):e3088 journal.pone.0003088">CrossRef
  11. Kool M, Korshunov A, Remke M, Jones DT, Schlanstein M et al (2012) Molecular subgroups of medulloblastoma: an international meta-analysis of transcriptome, genetic aberrations, and clinical data of WNT, SHH, Group 3, and Group 4 medulloblastomas. Acta Neuropathol 123(4):473-84 CrossRef
  12. Lafay-Cousin L, Bouffet E, Hawkins C, Amid A, Huang A et al (2009) Impact of radiation avoidance on survival and neurocognitive outcome in infant medulloblastoma. Curr Oncol 16(6):21-8 CrossRef
  13. McCabe MT, Ott HM, Ganji G, Korenchuk S, Thompson C, et al (2012) EZH2 inhibition as a therapeutic strategy for lymphoma with EZH2-activating mutations. Nature. doi:10.1038/nature11606
  14. Morin RD, Mendez-Lago M, Mungall AJ, Goya R, Mungall KL et al (2011) Frequent mutation of histone-modifying genes in non-Hodgkin lymphoma. Nature 476(7360):298-03 CrossRef
  15. Northcott PA, Korshunov A, Witt H, Hielscher T, Eberhart CG et al (2011) Medulloblastoma comprises four distinct molecular variants. J Clin Oncol 29(11):1408-414 CrossRef
  16. Northcott PA, Nakahara Y, Wu X, Feuk L, Ellison DW et al (2009) Multiple recurrent genetic events converge on control of histone lysine methylation in medulloblastoma. Nat Genet 41(4):465-72 CrossRef
  17. Parsons DW, Li M, Zhang X, Jones S, Leary RJ et al (2011) The genetic landscape of the childhood cancer medulloblastoma. Science 331(6016):435-39 CrossRef
  18. Pfaff E, Remke M, Sturm D, Benner A, Witt H et al (2010) TP53 mutation is frequently associated with CTNNB1 mutation or MYCN amplification and is compatible with long-term survival in medulloblastoma. J Clin Oncol 28(35):5188-196 CrossRef
  19. Pugh TJ, Weeraratne SD, Archer TC, Pomeranz Krummel DA, Auclair D et al (2012) Medulloblastoma exome sequencing uncovers subtype-specific somatic mutations. Nature 488(7409):106-10 CrossRef
  20. Robinson G, Parker M, Kranenburg TA, Lu C, Chen X et al (2012) Novel mutations target distinct subgroups of medulloblastoma. Nature 488(7409):43-8 CrossRef
  21. Rudin CM, Hann CL, Laterra J, Yauch RL, Callahan CA et al (2009) Treatment of medulloblastoma with hedgehog pathway inhibitor GDC-0449. N Engl J Med 361(12):1173-178 CrossRef
  22. Schuettengruber B, Chourrout D, Vervoort M, Leblanc B, Cavalli G (2007) Genome regulation by polycomb and trithorax proteins. Cell 128(4):735-45 j.cell.2007.02.009">CrossRef
  23. Schuettengruber B, Martinez AM, Iovino N, Cavalli G (2011) Trithorax group proteins: switching genes on and keeping them active. Nat Rev Mol Cell Biol 12(12):799-14 CrossRef
  24. Tamayo P, Cho YJ, Tsherniak A, Greulich H, Ambrogio L et al (2011) Predicting relapse in patients with medulloblastoma by integrating evidence from clinical and genomic features. J Clin Oncol 29(11):1415-423 CrossRef
  25. Taylor MD, Northcott PA, Korshunov A, Remke M, Cho YJ et al (2012) Molecular subgroups of medulloblastoma: the current consensus. Acta Neuropathol 123(4):465-72 CrossRef
  
• 作者单位：Adrian M. Dubuc (1) (2) (3)
  Marc Remke (1) (2) (3)
  Andrey Korshunov (4) (5) (6)
  Paul A. Northcott (6)
  Shing H. Zhan (7)
  Maria Mendez-Lago (7)
  Marcel Kool (6)
  David T. W. Jones (6)
  Alexander Unterberger (1) (2)
  A. Sorana Morrissy (1) (2)
  David Shih (1) (2) (3)
  John Peacock (1) (2) (3)
  Vijay Ramaswamy (1) (2) (3)
  Adi Rolider (1) (2)
  Xin Wang (1) (2) (3)
  Hendrik Witt (6)
  Thomas Hielscher (6)
  Cynthia Hawkins (1) (2) (3)
  Rajeev Vibhakar (8)
  Sidney Croul (9)
  James T. Rutka (1) (3)
  William A. Weiss (10)
  Steven J. M. Jones (7)
  Charles G. Eberhart (11)
  Marco A. Marra (7)
  Stefan M. Pfister (6)
  Michael D. Taylor (1) (2) (3)
  
  1. Division of Neurosurgery, Arthur & Sonia Labatt Brain Tumour Research Centre, The Hospital for Sick Children, Toronto, ON, Canada
  2. Program in Developmental & Stem Cell Biology, The Hospital for Sick Children, 555 University Avenue, Toronto, ON, Canada
  3. Department of Laboratory Medicine & Pathobiology, University of Toronto, Toronto, ON, Canada
  4. CCU Neuropathology, German Cancer Research Centre (DKFZ), Heidelberg, Germany
  5. Department of Neuropathology, University of Heidelberg, Heidelberg, Germany
  6. Division of Pediatric Neurooncology, German Cancer Research Centre (DKFZ), Heidelberg, Germany
  7. Genome Sciences Centre, British Columbia Cancer Agency, Vancouver, BC, Canada
  8. Department of Pediatrics, The Children’s Hospital and University of Colorado, Anschutz Medical Campus, Colorado, USA
  9. Department of Pathology, University Health Network, University of Toronto, Toronto, ON, Canada
  10. Helen Diller Family Comprehensive Cancer Centre, University of California, San Francisco, CA, USA
  11. Department of Pathology, Johns Hopkins University, Baltimore, MD, USA
  
• ISSN：1432-0533

文摘

Recent sequencing efforts have described the mutational landscape of the pediatric brain tumor medulloblastoma. Although MLL2 is among the most frequent somatic single nucleotide variants (SNV), the clinical and biological significance of these mutations remains uncharacterized. Through targeted re-sequencing, we identified mutations of MLL2 in 8?% (14/175) of MBs, the majority of which were loss of function. Notably, we also report mutations affecting the MLL2-binding partner KDM6A, in 4?% (7/175) of tumors. While MLL2 mutations were independent of age, gender, histological subtype, M-stage or molecular subgroup, KDM6A mutations were most commonly identified in Group 4 MBs, and were mutually exclusive with MLL2 mutations. Immunohistochemical staining for H3K4me3 and H3K27me3, the chromatin effectors of MLL2 and KDM6A activity, respectively, demonstrated alterations of the histone code in 24?% (53/220) of MBs across all subgroups. Correlating these MLL2- and KDM6A-driven histone marks with prognosis, we identified populations of MB with improved (K4+/K27? and dismal (K4?K27? outcomes, observed primarily within Group 3 and 4 MBs. Group 3 and 4 MBs demonstrate somatic copy number aberrations, and transcriptional profiles that converge on modifiers of H3K27-methylation (EZH2, KDM6A, KDM6B), leading to silencing of PRC2-target genes. As PRC2-mediated aberrant methylation of H3K27 has recently been targeted for therapy in other diseases, it represents an actionable target for a substantial percentage of medulloblastoma patients with aggressive forms of the disease.